2022 Fiscal Year Final Research Report
Development of a new prognostic model and a method of assessing minimal residual disease for adult T-cell leukemia/lymphoma
| Project/Area Number |
19K17861
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 成人T細胞白血病リンパ腫 / 同種造血細胞移植 / 予後予測モデル / 微小残存病変 |
|---|
| Outline of Final Research Achievements |
In this study, we collected clinical information and specimens from patients with adult T-cell leukemia/lymphoma and developed a new prognostic model based on the ability to express Tax, a virus-specific antigen. We found that compared to patients who can express Tax, those who cannot express Tax have inferior overall survival and response to anti-CCR4 antibody drugs.
We evaluated minimal residual disease by using flow cytometry and mass cytometry before and after allogeneic transplantation. Our flow cytometry method had a positive predictive value of 80.0% and a negative predictive value of 85.7%. The results also suggest that this method can be used to predict recurrence and provide therapeutic intervention at an early stage.
|
| Free Research Field |
血液、腫瘍内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
成人T細胞白血病リンパ腫はHTLV-1感染に起因する、極めて予後不要な末梢性T細胞リンパ腫である。種々の治療開発が行われてきたが、現時点で治癒が期待できる治療法が同種造血細胞移植のみであり、いかに適切な症例に、最適な移植法を提供するかが重要である。
本研究で構築したTaxの発現能に基づく新たな予後予測モデルは、適切な移植症例の選択に有用であり、また本研究で検討したフローサイトメトリー・マスサイトメトリーを使用した同種移植前後の微小残存病変の評価法は、移植後再発抑制に繋がると考えられる。
|
